Attenuation of dexamethasone-induced cell death in multiple myeloma is mediated by miR-125b expression

Cell Cycle

Volumn 12, Issue 13, 2013, Pages 2144-2153

  Murray, Megan Y ^a   Rushworth, Stuart A ^a   Zaitseva, Lyubov ^a   Bowles, Kristian M ^b   MacEwan, David J ^a,c  

^a UNIVERSITY OF EAST ANGLIA   (United Kingdom)

^b NORFOLK AND NORWICH UNIVERSITY HOSPITAL   (United Kingdom)

^c UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

mir 125b; mir 34a; NF B; p53; SIRT1

Indexed keywords

DEXAMETHASONE; MESSENGER RNA; MICRORNA 125B; MICRORNA 34A; PROTEIN P53; SIRTUIN 1;

ACETYLATION; APOPTOSIS; ARTICLE; B LYMPHOCYTE; CELL DEATH; CONTROLLED STUDY; GENE EXPRESSION; GENE TARGETING; HUMAN; HUMAN CELL; MULTIPLE MYELOMA; PROTEIN EXPRESSION;

EID: 84879762974     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.25251     Document Type: Article

References (56)

1. Marcucci G, Mrózek K, Radmacher MD, Garzon R, Bloomfield CD. The prognostic and functional role of microRNAs in acute myeloid leukemia. Blood 2011; 117:1121-9; PMID:21045193; http://dx.doi.org/10.1182/blood-2010-09-191312
2. Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, et al. MicroRNA expression profiles classify human cancers. Nature 2005; 435:834-8; PMID:15944708; http://dx.doi.org/10.1038/nature03702
3. Garzon R, Garofalo M, Martelli MP, Briesewitz R, Wang L, Fernandez-Cymering C, et al. Distinctive microRNA signature of acute myeloid leukemia bearing cytoplasmic mutated nucleophosmin. Proc Natl Acad Sci USA 2008; 105:3945-50; PMID:18308931; http://dx.doi.org/10.1073/pnas.0800135105
4. Melino G, Knight RA. MicroRNAs meet cell death. Cell Death Differ 2010; 17:189-90; PMID:20062066; http://dx.doi.org/10.1038/cdd.2009.122
5. Shaham L, Binder V, Gefen N, Borkhardt A, Izraeli S. miR-125 in normal and malignant hematopoiesis. Leukemia 2012; 26:2011-8; PMID:22456625; http://dx.doi.org/10.1038/leu.2012.90
6. Le MT, Teh C, Shyh-Chang N, Xie H, Zhou B, Korzh V, et al. MicroRNA-125b is a novel negative regulator of p53. Genes Dev 2009; 23:862-76; PMID:19293287; http://dx.doi.org/10.1101/gad.1767609
7. Zhou M, Liu Z, Zhao Y, Ding Y, Liu H, Xi Y, et al. MicroRNA-125b confers the resistance of breast cancer cells to paclitaxel through suppression of proapoptotic Bcl-2 antagonist killer 1 (Bak1) expression. J Biol Chem 2010; 285:21496-507; PMID:20460378; http://dx.doi.org/10.1074/jbc.M109.083337
8. Schotte D, De Menezes RX, Akbari Moqadam F, Khankahdani LM, Lange-Turenhout E, Chen C, et al. MicroRNA characterize genetic diversity and drug resistance in pediatric acute lymphoblastic leukemia. Haematologica 2011; 96:703-11; PMID:21242186; http://dx.doi.org/10.3324/haematol.2010.026138
9. Yan K, Gao J, Yang T, Ma Q, Qiu X, Fan Q, et al. MicroRNA-34a inhibits the proliferation and metastasis of osteosarcoma cells both in vitro and in vivo. PLoS One 2012; 7:e33778; PMID:22457788; http://dx.doi.org/10.1371/journal. pone.0033778
10. Welch C, Chen Y, Stallings RL. MicroRNA-34a functions as a potential tumor suppressor by inducing apoptosis in neuroblastoma cells. Oncogene 2007; 26:5017-22; PMID:17297439; http://dx.doi.org/10.1038/sj.onc.1210293
11. Chang TC, Wentzel EA, Kent OA, Ramachandran K, Mullendore M, Lee KH, et al. Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis. Mol Cell 2007; 26:745-52; PMID:17540599; http://dx.doi.org/10.1016/j.molcel.2007.05.010
12. Yamakuchi M, Ferlito M, Lowenstein CJ. miR-34a repression of SIRT1 regulates apoptosis. Proc Natl Acad Sci USA 2008; 105:13421-6; PMID:18755897; http://dx.doi.org/10.1073/pnas.0801613105
13. Peurala H, Greco D, Heikkinen T, Kaur S, Bartkova J, Jamshidi M, et al. miR-34a expression has an effect for lower risk of metastasis and associates with expression patterns predicting clinical outcome in breast cancer. PLoS One 2011; 6:e26122; PMID:22102859; http://dx.doi.org/10.1371/journal.pone.0026122
14. Audrito V, Vaisitti T, Rossi D, Gottardi D, D'Arena G, Laurenti L, et al. Nicotinamide blocks proliferation and induces apoptosis of chronic lymphocytic leukemia cells through activation of the p53/miR-34a/SIRT1 tumor suppressor network. Cancer Res 2011; 71:4473-83; PMID:21565980; http://dx.doi.org/10.1158/ 0008-5472.CAN-10-4452
15. Vinall RL, Ripoll AZ, Wang S, Pan CX, deVere White RW. miR-34a chemosensitizes bladder cancer cells to cisplatin treatment regardless of p53-Rb pathway status. Int J Cancer 2012; 130:2526-38; PMID:21702042; http://dx.doi.org/10.1002/ijc.26256
16. Weeraratne SD, Amani V, Neiss A, Teider N, Scott DK, Pomeroy SL, et al. miR-34a confers chemosensitivity through modulation of MAGE-A and p53 in medulloblastoma. Neuro Oncol 2011; 13:165-75; PMID:21177782; http://dx.doi.org/10.1093/neuonc/noq179
17. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010; 127:2893-917; PMID:21351269; http://dx.doi.org/10.1002/ijc.25516
18. Bird JM, Owen RG, D'Sa S, Snowden JA, Pratt G, Ashcroft J, et al.; Haemato-oncology Task Force of British Committee for Standards in Haematology (BCSH) and UK Myeloma Forum. Guidelines for the diagnosis and management of multiple myeloma 2011. Br J Haematol 2011; 154:32-75; PMID:21569004; http://dx.doi.org/10.1111/j.1365-2141.2011.08573.x
19. Rowland TL, McHugh SM, Deighton J, Ewan PW, Dearman RJ, Kimber I. Differential effect of thalidomide and dexamethasone on the transcription factor NFkappa B. Int Immunopharmacol 2001; 1:49-61; PMID:11367517; http://dx.doi.org/10.1016/S0162-3109(00)00265-4
20. Murphy SH, Suzuki K, Downes M, Welch GL, De Jesus P, Miraglia LJ, et al. Tumor suppressor protein (p)53, is a regulator of NFkappaB repression by the glucocorticoid receptor. Proc Natl Acad Sci USA 2011; 108:17117-22; PMID:21949408; http://dx.doi.org/10.1073/pnas.1114420108
21. Langenau DM, Jette C, Berghmans S, Palomero T, Kanki JP, Kutok JL, et al. Suppression of apoptosis by bcl-2 overexpression in lymphoid cells of transgenic zebrafish. Blood 2005; 105:3278-85; PMID:15618471; http://dx.doi.org/10.1182/blood-2004-08-3073
22. Norman M, Hearing SD. Glucocorticoid resistance - what is known? Curr Opin Pharmacol 2002; 2:723-9; PMID:12482737; http://dx.doi.org/10.1016/S1471- 4892(02)00232-1
23. Kotani A, Ha D, Hsieh J, Rao PK, Schotte D, den Boer ML, et al. miR-128b is a potent glucocorticoid sensitizer in MLL-AF4 acute lymphocytic leukemia cells and exerts cooperative effects with miR-221. Blood 2009; 114:4169-78; PMID:19749093; http://dx.doi.org/10.1182/blood-2008-12-191619
24. Chauhan D, Auclair D, Robinson EK, Hideshima T, Li G, Podar K, et al. Identification of genes regulated by dexamethasone in multiple myeloma cells using oligonucleotide arrays. Oncogene 2002; 21:1346-58; PMID:11857078; http://dx.doi.org/10.1038/sj.onc.1205205
25. Rushworth SA, Zaitseva L, Langa S, Bowles KM, MacEwan DJ. FLIP regulation of HO-1 and TNF signalling in human acute myeloid leukemia provides a unique secondary anti-apoptotic mechanism. Oncotarget 2010; 1:359-66; PMID:21307400
26. Chim CS, Wong KY, Qi Y, Loong F, Lam WL, Wong LG, et al. Epigenetic inactivation of the miR-34a in hematological malignancies. Carcinogenesis 2010; 31:745-50; PMID:20118199; http://dx.doi.org/10.1093/carcin/bgq033
27. Bousquet M, Harris MH, Zhou B, Lodish HF. MicroRNA miR-125b causes leukemia. Proc Natl Acad Sci USA 2010; 107:21558-63; PMID:21118985; http://dx.doi.org/10.1073/pnas.1016611107
28. Wang H, Tan G, Dong L, Cheng L, Li K, Wang Z, et al. Circulating miR-125b as a marker predicting chemoresistance in breast cancer. PLoS One 2012; 7:e34210; PMID:22523546; http://dx.doi.org/10.1371/journal.pone.0034210
29. Li J, Wang K, Chen X, Meng H, Song M, Wang Y, et al. Transcriptional activation of microRNA-34a by NFkappa B in human esophageal cancer cells. BMC Mol Biol 2012; 13:4; PMID:22292433; http://dx.doi.org/10.1186/1471-2199-13-4
30. Kim SW, Ramasamy K, Bouamar H, Lin AP, Jiang D, Aguiar RC. MicroRNAs miR-125a and miR-125b constitutively activate the NFκB pathway by targeting the tumor necrosis factor alpha-induced protein 3 (TNFAIP3, A20). Proc Natl Acad Sci USA 2012; 109:7865-70; PMID:22550173; http://dx.doi.org/10.1073/ pnas.1200081109
31. Petitjean A, Mathe E, Kato S, Ishioka C, Tavtigian SV, Hainaut P, et al. Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Hum Mutat 2007; 28:622-9; PMID:17311302; http://dx.doi.org/10.1002/humu.20495
32. Rushworth SA, Bowles KM, Barrera LN, Murray MY, Zaitseva L, MacEwan DJ. BTK inhibitor ibrutinib is cytotoxic to myeloma and potently enhances bortezomib and lenalidomide activities through NFκB. Cell Signal 2013; 25:106-12; PMID:22975686; http://dx.doi.org/10.1016/j.cellsig.2012.09.008
33. Calin GA, Dumitru CD, Shimizu M, Bichi R, Zupo S, Noch E, et al. Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci USA 2002; 99:15524-9; PMID:12434020; http://dx.doi.org/10.1073/pnas.242606799
34. Gururajan M, Haga CL, Das S, Leu CM, Hodson D, Josson S, et al. MicroRNA 125b inhibition of B cell differentiation in germinal centers. Int Immunol 2010; 22:583-92; PMID:20497960; http://dx.doi.org/10.1093/intimm/dxq042
35. Chaudhuri AA, So AY, Mehta A, Minisandram A, Sinha N, Jonsson VD, et al. Oncomir miR-125b regulates hematopoiesis by targeting the gene Lin28A. Proc Natl Acad Sci USA 2012; 109:4233-8; PMID:22366319
36. Enomoto Y, Kitaura J, Hatakeyama K, Watanuki J, Akasaka T, Kato N, et al. Eμ/miR-125b transgenic mice develop lethal B-cell malignancies. Leukemia 2011; 25:1849-56; PMID:21738213; http://dx.doi.org/10.1038/leu.2011.166
37. Cai B, Wang S, Huang J, Lee CK, Gao C, Liu B. Cladribine and bendamustine exhibit inhibitory activity in dexamethasone-sensitive and -resistant multiple myeloma cells. Am J Transl Res 2013; 5:36-46; PMID:23390564
38. Kastl L, Brown I, Schofield AC. miRNA-34a is associated with docetaxel resistance in human breast cancer cells. Breast Cancer Res Treat 2012; 131:445-54; PMID:21399894; http://dx.doi.org/10.1007/s10549-011-1424-3
39. Kojima K, Fujita Y, Nozawa Y, Deguchi T, Ito M. miR-34a attenuates paclitaxel-resistance of hormone-refractory prostate cancer PC3 cells through direct and indirect mechanisms. Prostate 2010; 70:1501-12; PMID:20687223; http://dx.doi.org/10.1002/pros.21185
40. Moran TJ, Gray S, Mikosz CA, Conzen SD. The glucocorticoid receptor mediates a survival signal in human mammary epithelial cells. Cancer Res 2000; 60:867-72; PMID:10706096
41. Sengupta S, Vonesch JL, Waltzinger C, Zheng H, Wasylyk B. Negative cross-talk between p53 and the glucocorticoid receptor and its role in neuroblastoma cells. EMBO J 2000; 19:6051-64; PMID:11080152; http://dx.doi.org/10.1093/emboj/19.22.6051
42. Shi L, Zhang S, Feng K, Wu F, Wan Y, Wang Z, et al. MicroRNA-125b-2 confers human glioblastoma stem cells resistance to temozolomide through the mitochondrial pathway of apoptosis. Int J Oncol 2012; 40:119-29; PMID:21879257
43. Fontana L, Fiori ME, Albini S, Cifaldi L, Giovinazzi S, Forloni M, et al. Antagomir-17-5p abolishes the growth of therapy-resistant neuroblastoma through p21 and BIM. PLoS One 2008; 3:e2236; PMID:18493594; http://dx.doi.org/10.1371/ journal.pone.0002236
44. Ma L, Reinhardt F, Pan E, Soutschek J, Bhat B, Marcusson EG, et al. Therapeutic silencing of miR-10b inhibits metastasis in a mouse mammary tumor model. Nat Biotechnol 2010; 28:341-7; PMID:20351690; http://dx.doi.org/10.1038/ nbt.1618
45. Muramatsu F, Kidoya H, Naito H, Sakimoto S, Takakura N. microRNA-125b inhibits tube formation of blood vessels through translational suppression of VE-cadherin. Oncogene 2013; 32:414-21; PMID:22391569; http://dx.doi.org/10.1038/ onc.2012.68
46. Stühmer T, Chatterjee M, Hildebrandt M, Herrmann P, Gollasch H, Gerecke C, et al. Nongenotoxic activation of the p53 pathway as a therapeutic strategy for multiple myeloma. Blood 2005; 106:3609-17; PMID:16081689; http://dx.doi.org/10.1182/blood-2005-04-1489
47. Wei S, Chen X, McGraw K, Zhang L, Komrokji R, Clark J, et al. Lenalidomide promotes p53 degradation by inhibiting MDM2 auto-ubiquitination in myelodysplastic syndrome with chromosome 5q deletion. Oncogene 2013; 32:1110-20; PMID:22525275
48. Cross B, Chen L, Cheng Q, Li B, Yuan ZM, Chen J. Inhibition of p53 DNA binding function by the MDM2 protein acidic domain. J Biol Chem 2011; 286:16018-29; PMID:21454483; http://dx.doi.org/10.1074/jbc.M111.228981
49. Chen MH, Qi CX, Saha MN, Chang H. p53 nuclear expression correlates with hemizygous TP53 deletion and predicts an adverse outcome for patients with relapsed/refractory multiple myeloma treated with lenalidomide. Am J Clin Pathol 2012; 137:208-12; PMID:22261445; http://dx.doi.org/10.1309/AJCPHC85DGAXZDBE
50. Sotillo E, Laver T, Mellert H, Schelter JM, Cleary MA, McMahon S, et al. Myc overexpression brings out unexpected antiapoptotic effects of miR-34a. Oncogene 2011; 30:2587-94; PMID:21297663; http://dx.doi.org/10.1038/onc.2010.634
51. Zeng CW, Zhang XJ, Lin KY, Ye H, Feng SY, Zhang H, et al. Camptothecin induces apoptosis in cancer cells via microRNA-125b-mediated mitochondrial pathways. Mol Pharmacol 2012; 81:578-86; PMID:22252650; http://dx.doi.org/10. 1124/mol.111.076794
52. Rae C, MacEwan DJ. Granulocyte macrophage-colony stimulating factor and interleukin-3 increase expression of type II tumor necrosis factor receptor, increasing susceptibility to tumor necrosis factor-induced apoptosis. Control of leukaemia cell life/death switching. Cell Death Differ 2004; 11(Suppl 2):S162-71; PMID:15459750; http://dx.doi.org/10.1038/sj.cdd.4401494
53. Rushworth SA, Bowles KM, Raninga P, MacEwan DJ. NFkappaB-inhibited acute myeloid leukemia cells are rescued from apoptosis by heme oxygenase-1 induction. Cancer Res 2010; 70:2973-83; PMID:20332229; http://dx.doi.org/10.1158/0008- 5472.CAN-09-3407
54. Rushworth SA, Bowles KM, MacEwan DJ. High basal nuclear levels of Nrf2 in acute myeloid leukemia reduces sensitivity to proteasome inhibitors. Cancer Res 2011; 71:1999-2009; PMID:21212410; http://dx.doi.org/10.1158/0008-5472.CAN-10- 3018
55. Rushworth SA, Zaitseva L, Murray MY, Shah NM, Bowles KM, MacEwan DJ. The high Nrf2 expression in human acute myeloid leukemia is driven by NFκB and underlies its chemo-resistance. Blood 2012; 120:5188-98; PMID:23077289; http://dx.doi.org/10.1182/blood-2012-04-422121
56. Barrera LN, Rushworth SA, Bowles KM, MacEwan DJ. Bortezomib induces heme oxygenase-1 expression in multiple myeloma. Cell Cycle 2012; 11:2248-52; PMID:22617388; http://dx.doi.org/10.4161/cc.20343